Teva to Present New Respiratory Data at 2015 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
20 Février 2015 - 2:00PM
Business Wire
New Data Showcases Teva’s Respiratory
Pipeline
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced
that four company-sponsored abstracts will be presented at the 2015
Annual Meeting of the American Academy of Allergy, Asthma and
Immunology (AAAAI) in Houston, Texas. Data to be presented include
two replicate 52-week Phase III global studies of the company’s
anti-IL5 monoclonal antibody, reslizumab, in patients with asthma
and elevated blood eosinophils who were inadequately controlled on
medium-to-high doses of inhaled corticosteroids (ICS) with or
without an additional controller. The data are scheduled for
presentation on Monday, February 23 during an oral session titled
“Asthma Therapy and Mechanisms.”
Also to be presented are two Phase III studies of beclomethasone
dipropionate 40mcg, which gained FDA approval in December 2014, and
is now available for the treatment of nasal symptoms associated
with allergic rhinitis in children 4-11 years of age. In addition,
a dose-response study evaluating the safety and efficacy of
fluticasone/salmeterol multidose dry-powder inhaler (FS MDPI) in
patients 12 years of age and older with persistent asthma will be
presented.
“The AAAAI annual meeting provides Teva with an opportunity to
showcase the strides we are making to optimize respiratory
therapies for patients through delivery systems and therapies
designed to address unmet needs,” said Tushar Shah, MD, Senior Vice
President, Teva Global Respiratory Research and Development. “We
are excited to present our data findings, particularly our Phase
III clinical trial results for reslizumab, as they represent a
pivotal step forward in providing severe asthma patients with new
treatment options.”
The following Teva-sponsored data will be presented at the 2015
AAAAI Annual Meeting:
Reslizumab
- Oral Presentation (#L1):
Reslizumab Treatment for Moderate to Severe Asthma with Elevated
Blood Eosinophil Levels
- Monday, February 23, 2015; 2:00-3:15
PM; Room 342, Level Three, George R. Brown Convention Center
Beclomethasone dipropionate 40 mcg
- Poster Presentation (#703):
Once-Daily Treatment with Beclomethasone Dipropionate (BDP) Nasal
Aerosol is Effective in Improving Total Nasal Symptom Scores (TNSS)
in Children with Seasonal Allergic Rhinitis (SAR) Regardless of
Baseline Symptom Severity
- Monday, February 23, 2015; 9:45-10:45
AM; Exhibit Hall B2, Level Three, George R. Brown Convention
Center
- Poster Presentation (#704):
Once-Daily Treatment with Beclomethasone Dipropionate Nasal Aerosol
Is Effective in Improving Total Nasal Symptom Scores (TNSS) in
Children with Perennial Allergic Rhinitis (PAR) Regardless of
Baseline Symptom Severity
- Monday, February 23, 2015; 9:45-10:45
AM; Exhibit Hall B2, Level Three, George R. Brown Convention
Center
Fluticasone
- Poster Presentation (#19):
Dose-Ranging Study to Evaluate the Efficacy and Safety of Four
Doses of Fluticasone Propionate/Salmeterol Multidose Dry Power
Inhaler Compared with Fluticasone Propionate Multidose Dry Powder
Inhaler and Fluticasone Propionate/Salmeterol Dry Powder Inhaler in
Patients 12 Years of Age or Older with Persistent Asthma
- Saturday, February 21, 2015; 9:45-10:45
AM; Exhibit Hall B2, Level Three, George R. Brown Convention
Center
All abstracts have been published in an online supplement to the
February issue of Journal of Allergy and Clinical Immunology.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
leading global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions to millions of patients every
day. Headquartered in Israel, Teva is the world’s largest generic
medicines producer, leveraging its portfolio of more than 1,000
molecules to produce a wide range of generic products in nearly
every therapeutic area. In specialty medicines, Teva has a
world-leading position in innovative treatments for disorders of
the central nervous system, including pain, as well as a strong
portfolio of respiratory products. Teva integrates its generics and
specialty capabilities in its global research and development
division to create new ways of addressing unmet patient needs by
combining drug development capabilities with devices, services and
technologies. Teva's net revenues in 2014 amounted to $20.3
billion. For more information, visit www.tevapharm.com.
Teva's Safe Harbor Statement under the U. S. Private
Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which are
based on management’s current beliefs and expectations and involve
a number of known and unknown risks and uncertainties that could
cause our future results, performance or achievements to differ
significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include
risks relating to: our ability to develop and commercialize
additional pharmaceutical products; competition for our innovative
products, especially Copaxone® (including competition from
orally-administered alternatives, as well as from potential
purported generic equivalents) and our ability to migrate users to
our new 40 mg/mL version; the possibility of material fines,
penalties and other sanctions and other adverse consequences
arising out of our ongoing FCPA investigations and related matters;
our ability to achieve expected results from the research and
development efforts invested in our pipeline of specialty and other
products; our ability to reduce operating expenses to the extent
and during the timeframe intended by our cost reduction program;
our ability to identify and successfully bid for suitable
acquisition targets or licensing opportunities, or to consummate
and integrate acquisitions; the extent to which any manufacturing
or quality control problems damage our reputation for quality
production and require costly remediation; increased government
scrutiny in both the U.S. and Europe of our patent settlement
agreements; our exposure to currency fluctuations and restrictions
as well as credit risks; the effectiveness of our patents,
confidentiality agreements and other measures to protect the
intellectual property rights of our specialty medicines; the
effects of reforms in healthcare regulation and pharmaceutical
pricing, reimbursement and coverage; governmental investigations
into sales and marketing practices, particularly for our specialty
pharmaceutical products; adverse effects of political or economic
instability, major hostilities or acts of terrorism on our
significant worldwide operations; interruptions in our supply chain
or problems with internal or third-party information technology
systems that adversely affect our complex manufacturing processes;
significant disruptions of our information technology systems or
breaches of our data security; competition for our generic
products, both from other pharmaceutical companies and as a result
of increased governmental pricing pressures; competition for our
specialty pharmaceutical businesses from companies with greater
resources and capabilities; the impact of continuing consolidation
of our distributors and customers; decreased opportunities to
obtain U.S. market exclusivity for significant new generic
products; potential liability in the U.S., Europe and other markets
for sales of generic products prior to a final resolution of
outstanding patent litigation; our potential exposure to product
liability claims that are not covered by insurance; any failure to
recruit or retain key personnel, or to attract additional executive
and managerial talent; any failures to comply with complex Medicare
and Medicaid reporting and payment obligations; significant
impairment charges relating to intangible assets, goodwill and
property, plant and equipment; the effects of increased leverage
and our resulting reliance on access to the capital markets;
potentially significant increases in tax liabilities; the effect on
our overall effective tax rate of the termination or expiration of
governmental programs or tax benefits, or of a change in our
business; variations in patent laws that may adversely affect our
ability to manufacture our products in the most efficient manner;
environmental risks; and other factors that are discussed in our
Annual Report on Form 20-F for the year ended December 31, 2014 and
in our other filings with the U.S. Securities and Exchange
Commission. Forward-looking statements speak only as of the date on
which they are made and we assume no obligation to update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise.
Teva Pharmaceutical Industries Ltd.IR:Kevin C.
Mannix, 215-591-8912United StatesorRan Meir,
215-591-3033United StatesorTomer Amitai, 972 (3)
926-7656IsraelorPR:Iris Beck Codner, 972 (3)
926-7687IsraelorDenise Bradley, 215-591-8974United
StatesorNancy Leone, 215-284-0213United States
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024